Get the Stockscreener App
12.79
1.46%
-0.19
Pre-market:
12.77
-0.02
-0.16%
Liquidia Corp stock is currently priced at $12.79, with a 24-hour trading volume of 343.57K.
It has seen a -1.46% decreased in the last 24 hours and a -16.68% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $13.06 pivot point. If it approaches the $12.77 support level, significant changes may occur.
Previous Close:
$12.98
Open:
$13.15
24h Volume:
343.57K
Market Cap:
$976.93M
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-16.61
EPS:
-0.77
Net Cash Flow:
$-52.85M
1W Performance:
+2.08%
1M Performance:
-16.68%
6M Performance:
+92.33%
1Y Performance:
+81.42%
1D Range:
$12.66
$13.23
52W Range:
$5.71
$16.99
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919-328-4400
Address
419 Davis Drive, Suite 100, Morrisville, NC
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
Zacks Investment Research
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
The Analyst Landscape: 5 Takes On Liquidia
Benzinga
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
GlobeNewswire Inc.
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Liquidia Corp Stock (LQDA) Financials Data
Liquidia Corp (LQDA) Revenue 2024
LQDA reported a revenue (TTM) of $17.49 million for the quarter ending December 31, 2023, a +9.75% rise year-over-year.
Liquidia Corp (LQDA) Net Income 2024
LQDA net income (TTM) was -$78.50 million for the quarter ending December 31, 2023, a -91.40% decrease year-over-year.
Liquidia Corp (LQDA) Cash Flow 2024
LQDA recorded a free cash flow (TTM) of -$52.85 million for the quarter ending December 31, 2023, a -81.13% decrease year-over-year.
Liquidia Corp (LQDA) Earnings per Share 2024
LQDA earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a -76.47% decline year-over-year.
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JEFFS ROGER | Chief Executive Officer |
Apr 12 '24 |
Sale |
14.58 |
8,360 |
121,889 |
826,985 |
| Kaseta Michael | CFO and COO |
Apr 12 '24 |
Sale |
14.58 |
3,136 |
45,723 |
315,045 |
| Schundler Russell | General Counsel |
Apr 12 '24 |
Sale |
14.58 |
2,060 |
30,035 |
486,027 |
| Moomaw Scott | Chief Commercial Officer |
Apr 12 '24 |
Sale |
14.58 |
1,585 |
23,109 |
151,881 |
| Saggar Rajeev | Chief Medical Officer |
Apr 12 '24 |
Sale |
14.58 |
1,525 |
22,234 |
213,321 |
| Adair Jason | Chief Business Officer |
Apr 12 '24 |
Sale |
14.58 |
1,189 |
17,336 |
111,537 |
| JEFFS ROGER | Chief Executive Officer |
Mar 18 '24 |
Sale |
15.82 |
28,583 |
452,183 |
835,345 |
| Kaseta Michael | CFO and COO |
Mar 18 '24 |
Sale |
15.82 |
12,166 |
192,466 |
318,181 |
| Schundler Russell | General Counsel |
Mar 18 '24 |
Sale |
15.82 |
8,653 |
136,890 |
488,087 |
| Saggar Rajeev | Chief Medical Officer |
Mar 18 '24 |
Sale |
15.82 |
7,530 |
119,125 |
214,846 |
About Liquidia Corp
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
1.62%
0.15%
Cap:
|
Volume (24h):